Pfizer (NYSE:PFE) Shares Gap Down – Here’s What Happened

Pfizer Inc. (NYSE:PFE)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $26.66, but opened at $25.36. Pfizer shares last traded at $25.7460, with a volume of 15,210,619 shares traded.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 earnings beat — Pfizer reported $0.66 EPS vs. consensus $0.57 and slight revenue outperformance, showing core profitability remains intact. Pfizer beats fourth-quarter profit estimates on strong drug demand (Reuters)
• Positive Sentiment: Promising obesity drug data — Mid‑stage results for Pfizer’s monthly GLP‑1 injection showed up to ~12–13% weight loss, supporting the company’s push into obesity treatments and adding a tangible pipeline catalyst. Pfizer’s experimental drug shows up to 12.3% weight loss in mid-stage trial (Reuters)
• Neutral Sentiment: Corporate materials and slides available — Management released the press release and slide deck with results and program updates, useful for modeling revenue mix and R&D timing. Q4 press release and slide deck (Pfizer)
• Negative Sentiment: Declining COVID product sales — Revenue continues to be pressured by lower demand for Pfizer’s COVID vaccine and antiviral, which drove year‑over‑year sales decline and limits near‑term top‑line growth. Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand (WSJ)
• Negative Sentiment: Guidance and profit outlook concerns — Management reaffirmed a modest 2026 outlook and flagged near‑term profit/revenue headwinds (including a cited ~$1.5B patent‑cliff impact), which keeps pressure on forward estimates. Pfizer projects annual revenue decline amid $1.5B hit from patent cliffs (Seeking Alpha)
• Negative Sentiment: Analyst caution and margin pressure — Some brokers (e.g., Goldman Sachs) keep Neutral ratings, citing rising margin pressure from patent expiries and pricing/policy risks; that dampens upside to consensus targets. Goldman Sachs Maintains Neutral on Pfizer (InsiderMonkey)

Wall Street Analyst Weigh In

PFE has been the subject of several analyst reports. Citigroup started coverage on Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price for the company. Zacks Research lowered shares of Pfizer from a “hold” rating to a “strong sell” rating in a research report on Monday, January 26th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 target price on shares of Pfizer in a report on Wednesday, November 5th. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. Finally, Wolfe Research set a $24.00 target price on Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $28.06.

Pfizer Price Performance

The stock has a market capitalization of $146.10 billion, a PE ratio of 14.92 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The firm’s 50 day simple moving average is $25.54 and its 200 day simple moving average is $25.05.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. During the same period in the prior year, the firm earned $0.63 earnings per share. Pfizer’s revenue was down 1.2% on a year-over-year basis. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Institutional Investors Weigh In On Pfizer

Large investors have recently added to or reduced their stakes in the company. MGO One Seven LLC lifted its position in Pfizer by 33.6% during the 4th quarter. MGO One Seven LLC now owns 143,176 shares of the biopharmaceutical company’s stock valued at $3,565,000 after acquiring an additional 36,045 shares during the period. Premier Fund Managers Ltd purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $10,917,000. Sequoia Financial Advisors LLC boosted its position in shares of Pfizer by 1.0% in the 4th quarter. Sequoia Financial Advisors LLC now owns 338,836 shares of the biopharmaceutical company’s stock worth $8,437,000 after purchasing an additional 3,498 shares in the last quarter. WealthShield Partners LLC grew its stake in shares of Pfizer by 5.3% in the 4th quarter. WealthShield Partners LLC now owns 26,545 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 1,328 shares during the last quarter. Finally, Gateway Investment Advisers LLC increased its position in Pfizer by 13.8% during the 4th quarter. Gateway Investment Advisers LLC now owns 66,978 shares of the biopharmaceutical company’s stock valued at $1,668,000 after buying an additional 8,147 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.